Subsequently, both administrations of IL-1β-neutralising antibodies or the CCR2/CCR5 dual antagonist, cenicriviroc, to block migration of myeloid cells, was sufficient to substantially reduce infiltration of monocytes into the heart, reduce cardiac fibrosis and prevent cardiac dysfunction post-stroke. This evidence concerns the gene IL1B and stroke disorder.